Scalper1 News
Celgene (CELG) late Tuesday said it will pay $232 a share in cash for Receptos (RCPT), and announced strong Q2 earnings and sales figures. The biotech giant said the deal “significantly enhances Celgene’s inflammation & immunology portfolio,” Receptos, which is developing treatments for multiple sclerosis and ulcerative-colitis, rose 10.2% to 228.25 in after-hours action after being halted on the deal announcement. The stock had closed up 5.1% to Scalper1 News
Scalper1 News